Development and potential use of a monoclonal antibody to the lipopolysaccharide of Pantoea agglomerans (IP-PA1).
BACKGROUND
The lipopolysaccharide of Pantoea agglomerans (IP-PA ) has been shown to be effective and safe in the prevention of various diseases, such as bacterial or viral infection, lifestyle-related diseases, when administered transdermally or orally. To clarify the mechanisms of the preventive or therapeutic effect induced by IP-PA1, we tried to establish a monoclonal antibody to detect IP-PA1. The enzyme-linked immunosorbent assay (ELISA) was used to measure the amount of IP-PA1.


METHODS
Antibodies were raised by immunization using heat-killed Pantoea agglomerans and screening was conducted to isolate monoclonal antibodies specific to IP-PA1.


RESULTS
Six kinds of IP-PA1 specific monoclonal antibodies with different epitopes were established. An ELISA using the monoclonal antibodies was successfully established which could specifically detect IP-PA1.


CONCLUSIONS
By use of this ELISA, the staple food content and pharmacodynamic analysis of IP-PA1 could be conveniently estimated.
Taniguchi
Yoshie
Y
Institute for Health Sciences, Tokushima Bunri University, Nishihama, Yamashiro-cho, Tokushima-shi, Tokushima, Japan.
Nishizawa
Takashi
T
Honda
Teruko
T
Yoshioka
Noriko
N
Inagawa
Hiroyuki
H
Kohchi
Chie
C
Soma
Gen-Ichiro
G
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis*; D000918:Antibody Specificity; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D006825:Hybridomas; D008070:Lipopolysaccharides / Q000276:immunology* / Q000302:isolation & purification; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D020636:Pantoea / Q000276:immunology / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D008070:Lipopolysaccharides; C524847:lipopolysaccharide IP-PA1, Pantoea agglomerans